SAN DIEGO, Dec. 20, 2018 /PRNewswire/ -- Mirati
Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted
oncology company, today announced that it has been selected for
addition to the NASDAQ Biotechnology Index® (Nasdaq:
^NBI). The Company's addition to the Index will become effective
prior to market open on Monday, December 24,
2018.
The NASDAQ Biotechnology Index is designed to track the
performance of a set of securities listed on The NASDAQ Stock
Market® (NASDAQ®) that are classified as either biotechnology or
pharmaceutical according to the Industry Classification Benchmark
(ICB). Companies in the NBI must meet eligibility requirements,
including minimum market capitalization, average daily trading
volume, and seasoning as a public company, among other criteria.
The index is evaluated semi-annually in May and November and serves
as the basis for the iShares NASDAQ Biotechnology Index Fund
(Nasdaq: IBB). For more information about the NASDAQ Biotechnology
Index, including eligibility criteria,
visit https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Mirati Therapeutics
Mirati Therapeutics, Inc. is
a clinical-stage oncology company developing product candidates to
address the genetic, epigenetic and immunological promoters of
cancer. Our precision oncology clinical programs utilize
next-generation genomic testing to identify and select cancer
patients who we believe would be most likely to benefit from
targeted drug treatment. In immuno-oncology, we are advancing
clinical programs where our product candidates have the potential
to improve the immune environment of tumor cells and may enhance
and expand the efficacy of existing cancer immunotherapy medicines
when given in combination. Our pre-clinical programs include
potentially first-in-class and best-in-class product candidates
specifically designed to address mutations and tumors where few
treatment options exist. We approach each of our discovery and
development programs with a singular focus: to translate our deep
understanding of the molecular drivers of cancer into better
therapies and better outcomes for patients. For more information,
visit www.mirati.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mirati-therapeutics-added-to-nasdaq-biotechnology-index-300769914.html
SOURCE Mirati Therapeutics, Inc.